Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
Immunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs was first described in November 201...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.00515/full |
| _version_ | 1818312374927491072 |
|---|---|
| author | Hongjing Zang Jinwu Peng Hongmei Zheng Songqing Fan |
| author_facet | Hongjing Zang Jinwu Peng Hongmei Zheng Songqing Fan |
| author_sort | Hongjing Zang |
| collection | DOAJ |
| description | Immunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs was first described in November 2016. Since then, a series of cases of HPD after ICIs have been reported. Notwithstanding that only a small subset of patients may experience this atypical response, HPD in affected patients means shorter survival times and worse prognoses. We summarized common standards for HPD diagnosis and profiled advantages and disadvantages. Elderly age, MDM2 family amplification, infiltration of PD-1-positive regulatory effector T cells and M2-like macrophages, and cancer stem cells may take part in HPD occurrence. Overall, we should focus on investigating the early markers and pathogenic mechanisms of HPD to solve this issue in ICIs. |
| first_indexed | 2024-12-13T08:16:51Z |
| format | Article |
| id | doaj.art-f5377a7ffeb84dfb8d4b408bb82f3e68 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T08:16:51Z |
| publishDate | 2020-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f5377a7ffeb84dfb8d4b408bb82f3e682022-12-21T23:54:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-04-011010.3389/fonc.2020.00515512742Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and HypothesesHongjing Zang0Jinwu Peng1Hongmei Zheng2Songqing Fan3Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pathology, Xiangya Basic Medical School, Central South University, Changsha, ChinaDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, ChinaImmunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs was first described in November 2016. Since then, a series of cases of HPD after ICIs have been reported. Notwithstanding that only a small subset of patients may experience this atypical response, HPD in affected patients means shorter survival times and worse prognoses. We summarized common standards for HPD diagnosis and profiled advantages and disadvantages. Elderly age, MDM2 family amplification, infiltration of PD-1-positive regulatory effector T cells and M2-like macrophages, and cancer stem cells may take part in HPD occurrence. Overall, we should focus on investigating the early markers and pathogenic mechanisms of HPD to solve this issue in ICIs.https://www.frontiersin.org/article/10.3389/fonc.2020.00515/fullICIsimmunotherapyHPDPD-1PD-L1CTLA-4 |
| spellingShingle | Hongjing Zang Jinwu Peng Hongmei Zheng Songqing Fan Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses Frontiers in Oncology ICIs immunotherapy HPD PD-1 PD-L1 CTLA-4 |
| title | Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses |
| title_full | Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses |
| title_fullStr | Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses |
| title_full_unstemmed | Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses |
| title_short | Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses |
| title_sort | hyperprogression after immune checkpoint inhibitor treatment characteristics and hypotheses |
| topic | ICIs immunotherapy HPD PD-1 PD-L1 CTLA-4 |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.00515/full |
| work_keys_str_mv | AT hongjingzang hyperprogressionafterimmunecheckpointinhibitortreatmentcharacteristicsandhypotheses AT jinwupeng hyperprogressionafterimmunecheckpointinhibitortreatmentcharacteristicsandhypotheses AT hongmeizheng hyperprogressionafterimmunecheckpointinhibitortreatmentcharacteristicsandhypotheses AT songqingfan hyperprogressionafterimmunecheckpointinhibitortreatmentcharacteristicsandhypotheses |